Xconomy

APRIL 8, 2019

If you’ve been following venture capital trends, what you expected to happen in the first quarter of 2019 did: More money is being invested in fewer deals, and women founders still are getting less of it than men. Venture firms sent $32.6

Venture Capital 109

Venture Capital Capital Invest Startup 109

Xconomy

JULY 31, 2019

We at Xconomy are excited to announce that we are honoring Mark Levin, co-founder and partner at Third Rock Ventures, with our 2019 Lifetime Achievement Award in Boston. The award recognizes Levin’s extensive contributions to the biotech industry and to the Boston life sciences ecosystem.

Venture Capital 97

Venture Capital Capital Entrepreneur Help 97

Xconomy

JANUARY 28, 2019

Venture capital firms invest in potentially disruptive technologies with the hope of profit, then keep watch for further advances that could overtake their existing portfolio companies. Palo Alto, CA-based Norwest weathers the uncertainties of technology and the economy with an investing strategy. Read more » Reprints | Share:

Venture Capital 67

Venture Capital Marketing Guide Invest 67

Xconomy

JULY 17, 2020

If it seems like biotech investments have defied the financial headwinds of the pandemic, maybe it’s because they have. In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. It’s the biotech sector’s largest proportion of the top 25.

Venture Capital 90

Venture Capital Invest Research Capital 90

socalTECH

DECEMBER 26, 2018

In my new role as the first executive director for the Alliance for Southern California Innovation, I spent a lot of time outside of my home turf of Pasadena -- visiting innovation nodes such as San Diego, Irvine, Riverside, Santa Barbara, Venice, Santa Monica, and others.

Southern California 113

Southern California SoCal Pasadena Riverside 113

Xconomy

OCTOBER 23, 2018

Ed Kaye stepped aside from Sarepta Therapeutics (NASDAQ: SRPT ) last year after leading the company through one of the most noteworthy and controversial drug approvals in recent memory, for the Duchenne muscular dystrophy drug eteplirsen (Exondys 51). But his hiatus from a publicly traded biotech could be short-lived.

Funding 101

Funding Startup Help Develop 101

Xconomy

MAY 9, 2019

To date in 2019, 23 healthcare-related companies have gone public, the most of any sector. According to IPO research firm Renaissance Capital , 47 IPOs have priced so far this year across all sectors, down 27 percent compared to the same period in 2018. Just as last year, healthcare IPOs lead the way. Here’s a look.

Pricing 110

Pricing Research Capital Marketing 110